Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares. The company’s Q4 missed estimates, though its Analyst Day laid out a case for sustainable growth of 25% or more through 2027, highlighted by ongoing penetration into the BPH opportunity, strategy changes geared towards increasing utilization and more visibility into the business, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics price target lowered to $34 from $50 at TD Cowen
- Procept BioRobotics price target lowered to $28 from $50 at Piper Sandler
- PROCEPT BioRobotics Highlights Growth Strategy at Investor Day
- Procept BioRobotics sees FY26 revenue growth 27%-33%
- Procept BioRobotics downgraded to Perform from Outperform at Oppenheimer